Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Encysive Pharmaceuticals Inc.

Division of Pfizer Inc.
www.encysive.com

Latest From Encysive Pharmaceuticals Inc.

Distortion And Inflation In Measuring Pharma M&A

Five companies in big pharma’s top 20 have come through mergers in the past 10 years or so that changed them significantly. As measured by standard financial performance parameters, the processes at Takeda and Teva (and to some extent, at Allergan) seem relatively smooth and productive. Those at Pfizer and Merck don’t. But it depends on how you look at the numbers.

Deals Business Strategies

Stockwatch: Bluebird, Arrowhead And Short Memories

Last year's platform failure and back to the drawing board status of bluebird bio was all forgotten last week as data on a few patients treated with its CAR-T therapy were released. It seems that investors are quick to forget similar failed or problematic products at Arrowhead, uniQure and Juno.

Clinical Trials ImmunoOncology

Stockwatch: Earnings Season Turns Into Silly Season

A clinical trial failure at Auris and a revoked patent at Johnson & Johnson that will lead to the emergence of real US biosimilar competition passed virtually unnoticed last week. It's that time of year again.

Commercial BioPharmaceutical

Deals of the Week: Allergan/MAP, Actavis/Uteron, Baxter/Ipsen, and More

Allergan’s buyout of MAP Pharma is an unusual case of a deal centered on drug under the shadow of a “complete response” letter, but it’s not the only one. How does it compare to recent precedents.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Texas Biotechnology Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Pfizer Inc.
  • Senior Management
  • George W Cole, Pres. & CEO
    Richard Dixon, PhD, SVP, Research & CSO
  • Contact Info
  • Encysive Pharmaceuticals Inc.
    Phone: (713) 796-8822
    4848 Loop Central Dr., 7th Fl.
    Houston, TX 77081
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register